N. Lakhani

发表

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Melissa L. Johnson, A. El-Khoueiry, J. Rodon, 2021, Clinical Cancer Research.

A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies.

R. Messmann, A. Al-Katib, B. Klencke, 2021, Clinical lymphoma, myeloma & leukemia.

Development of a Center for Personalized Cancer Care at a Regional Cancer Center: Feasibility Trial of an Institutional Tumor Sequencing Advisory Board.

B. Lane, D. Chesla, S. Cottingham, 2015, The Journal of molecular diagnostics : JMD.

Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

M. Maris, C. Jacobson, A. Al-Katib, 2021, Clinical lymphoma, myeloma & leukemia.

2‐Methoxyestradiol, a Promising Anticancer Agent

W. Figg, J. Venitz, N. Lakhani, 2003, Pharmacotherapy.

Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol.

T. Veenstra, A. Sparreboom, Xia Xu, 2007, Journal of pharmaceutical sciences.

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

R. Ferris, P. Moore, V. Ganju, 2022, Journal for ImmunoTherapy of Cancer.

A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

A. Patnaik, S. Im, Y. Lou, 2021 .

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

A. Drilon, M. Burkard, T. Owonikoko, 2020, The New England journal of medicine.

ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study

N. Ibrahim, S. Kesari, M. Ahluwalia, 2016 .

A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

T. Blondal, A. Tolcher, F. Janku, 2019, Annals of Oncology.

Spontaneous Regression of Refractory Diffuse Large B-Cell Lymphoma with Improvement in Immune Status with ART in a Patient with HIV: A Case Report and Literature Review

Hamza Hashmi, Birendra K.C., N. Lakhani, 2015, The American journal of case reports.

A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.

A. Tolcher, K. Papadopoulos, D. Rasco, 2018 .

A Phase I Study of Novel Bcl‐2/Bcl‐xL Inhibitor APG‐1252 in Patients with Advanced SCLC or Other Solid Tumor: OA12

D. Rasco, Y. Wu, Dajun Yang, 2018, Journal of Thoracic Oncology.

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

J. Pons, P. Squifflet, W. Kim, 2019, Blood.

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

F. Hodi, Y. Bang, P. LoRusso, 2019, Journal of Clinical Oncology.

Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors

K. Papadopoulos, G. Falchook, Judy S. Wang, 2020, Cancer Immunology, Immunotherapy.

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

A. Patnaik, G. Falchook, J. Palcza, 2022, ESMO open.

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.

E. Maher, P. Wen, H. Fine, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

D. Jäger, M. Shah, E. Rasmussen, 2020, Journal for ImmunoTherapy of Cancer.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

I. Weissman, H. Wakelee, B. Sikic, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiangiogenesis therapeutic strategies in prostate cancer.

G. Macpherson, W. Figg, J. Venitz, 2002 .

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors

S. Steinberg, E. Kohn, A. Sparreboom, 2006, Cancer biology & therapy.

A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer

S. Steinberg, P. Duray, O. Brawley, 2003, Acta oncologica.

Antiangiogenesis Therapeutic Strategies in Prostate Cancer

G. Macpherson, W. Figg, J. Venitz, 2004, Cancer and Metastasis Reviews.

A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.

D. Rasco, Dajun Yang, Y. Zhai, 2019, Journal of Clinical Oncology.

Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol

A. Sparreboom, W. Figg, J. Venitz, 2006, Anti-cancer drugs.

Evaluation of the Pharmacokinetic-Pharmacodynamic relationship, Metabolism and Plasma Protein Binding of the novel antitumor agent, 2-Methoxyestradiol (2ME2), following oral administration in patients with solid tumors.

N. Lakhani, 2005 .

Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry.

A. Sparreboom, W. Figg, J. Venitz, 2005, Rapid communications in mass spectrometry : RCM.

Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen‐Independent Prostate Cancer

H. Parnes, W. Figg, J. Gulley, 2003, Pharmacotherapy.

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

D. Xuan, M. Maitland, A. Tolcher, 2021, Clinical Cancer Research.

ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases

N. Ibrahim, S. Kesari, M. Ahluwalia, 2020, Clinical Cancer Research.

Phase I I T rial o f T halidomide a nd C armustine f or P atients With R ecurrent H igh-Grade G liomas

E. Maher, P. Wen, H. Fine, 2003 .

Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection.

A. Sparreboom, W. Figg, J. Venitz, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients

M. O’Connor-McCourt, T. Yap, T. Gruosso, 2020, Journal of Immunotherapy for Cancer.

First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.

K. Kelly, Melissa L. Johnson, Huanyu Chen, 2019, Journal of Clinical Oncology.

Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.

Melissa L. Johnson, K. Papadopoulos, Sang-We Kim, 2021 .

A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.

I. Weissman, B. Sikic, C. Takimoto, 2018 .

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

A. Drilon, Keunchil Park, Melissa L. Johnson, 2018 .

Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas.

B. Wang, B. Sikic, C. Takimoto, 2018 .

A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.

P. LoRusso, J. Pons, W. Messersmith, 2018 .

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.

F. Hodi, Y. Bang, L. Chow, 2021, The Lancet. Oncology.

A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.

J. Hecht, P. Philip, C. Takimoto, 2020 .

PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.

D. Xuan, M. Maitland, A. Tolcher, 2018 .

ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer.

N. Ibrahim, S. Kesari, M. Ahluwalia, 2016 .

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

A. Schram, I. Braña, P. Vickers, 2022, ESMO open.

SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer

J. Gainor, F. Jin, K. Lee, 2021, Annals of Oncology.

Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors

A. Tolcher, K. Papadopoulos, R. Lutz, 2019 .

A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors.

A. Mosley, D. Rasco, R. Messmann, 2019, Journal of Clinical Oncology.

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

J. Pons, P. Squifflet, W. Kim, 2020 .

Pharmacogenetics of estrogen metabolism and transport in relation to cancer.

A. Sparreboom, W. Figg, J. Venitz, 2003, Current drug metabolism.

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

S. Ansell, L. Miller, H. Lichenstein, 2017 .

Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.

D. Xuan, M. Maitland, A. Tolcher, 2018 .

OA 12.07 LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases

A. Drilon, B. Tuch, V. Velcheti, 2017 .

Evaluation of weekly dosing of CRLX101 alone and in combination with bevacizumab (bev) in patients (pts) with advanced solid tumors

A. Tolcher, S. Piha-Paul, A. Senderowicz, 2016 .

A retrospective analysis of tolerance and outcomes of cutaneous malignant melanoma in patients receiving adjuvant interferon-alpha 2B: a community oncology perspective.

A. Davis, T. Koehler, N. Lakhani, 2017, Journal of experimental therapeutics & oncology.

295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas

A. Patnaik, S. Fu, Y. Liu, 2020 .

A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.

C. Takimoto, A. Patnaik, G. Fleming, 2020 .

429 Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer

F. Rangwala, B. Ma, E. Hamilton, 2021, Journal for ImmunoTherapy of Cancer.

1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)

A. Tolcher, F. Janku, T. T. Poulsen, 2020, Annals of Oncology.

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.

I. Lowy, K. Papadopoulos, J. Crown, 2023, Journal of Clinical Oncology.

790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)

I. Lowy, O. Hamid, V. Janković, 2022, Annals of Oncology.

Abstract PR09: Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors

R. Sullivan, A. Tolcher, L. Denis, 2019 .

CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.

A. El-Khoueiry, H. Mamdani, A. Spira, 2020 .

498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01

Y. Bang, J. Pons, P. Squifflet, 2021, Journal for ImmunoTherapy of Cancer.

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)

U. Banerji, J. Powderly, N. Lakhani, 2024, ESMO open.

Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.

D. Rasco, Dajun Yang, Y. Zhai, 2020 .

First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.

D. Rasco, Dajun Yang, Y. Zhai, 2020 .